Trial Profile
A Multi-center, Randomized, Placebo-controlled, Double-blinded Then Open 2 Stages Clinical Trial to Evaluate the Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin China Pharmaceutical
- 15 Aug 2017 Status changed from recruiting to completed.
- 19 Aug 2016 New trial record